Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use

Postepy Dermatologii i Alergologii

Volumn 30, Issue 3, 2013, Pages 165-169

  Gutfreund, Katarzyna ^a   Bienias, Wojciech ^a   Szewczyk, Anna ^a   Kaszuba, Andrzej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Pimecrolimus; Tacrolimus; Topical calcineurin inhibitors

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE ACETATE; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; PIMECROLIMUS; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA AREATA; ALTERNATIVE MEDICINE; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; COLLAGEN SYNTHESIS; CYTOKINE PRODUCTION; DERMATOLOGY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG MECHANISM; DRUG USE; GENE MUTATION; HUMAN; LANGERHANS CELL; LICHEN PLANUS; LICHEN SCLEROSUS ET ATROPHICUS; MAST CELL; PATIENT CARE; PRURITUS; PSORIASIS; REMISSION; REVIEW; SEBORRHEIC DERMATITIS; SKIN DEFECT; SKINFOLD THICKNESS; TREATMENT RESPONSE; VACCINATION; VITILIGO;

EID: 84880110544     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: 10.5114/pdia.2013.35619     Document Type: Review

References (34)

1. Ruzicka T, Assmann T, Homey B. Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-80. (Pubitemid 29222302)
2. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002; 16: 100-14. (Pubitemid 34460707)
3. Tharp MD. Calcineurin inhibitors. Dermatol Ther 2002; 15: 325-32. (Pubitemid 36133860)
4. Surber C, Itin P, Büchner S. Clinical controversy on the effect of topical cyclosporin: what is the target site? Dermatology 1992; 185: 242-5.
5. Brown MM, Brown GC, Brown HC, et al. Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009; 127: 146-52.
6. Pacor ML, Biesi D, Carleto A, et al. Topical cyclosporine in the treatment of oral pemphigus. Minerva Stomatol 1998; 47: 183-6.
7. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228-41. (Pubitemid 34118380)
8. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 2005; 59: 969-74.
9. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-73. (Pubitemid 46998543)
10. Silny W, Sadowska A, Dańczak-Pazdrowska A, Polańska A.Application of tacrolimus in the treatment of skin diseases other than atopic dermatitis. Postep Derm Alergol 2011; 28: 41-5.
11. Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy 2009; 64: 276-8.
12. Healy E, Bentley A, Fidler C, et al. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twice-daily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164: 387-95.
13. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012; 26: 1045-60.
14. Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Exp Ophthalmol 2004; 32: 224-6.
15. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatments with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-81. (Pubitemid 38932289)
16. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861-73. (Pubitemid 47583524)
17. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-50. (Pubitemid 32577856)
18. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002; 138: 1259-60. (Pubitemid 35025714)
19. Pitarch G, Torrijos A, Mahquijes L, et al. Systemic absorption of topical tacrolimus in pyoderma gangrenosum. Acta Derm Venereol 2006; 86: 64-5. (Pubitemid 46939794)
20. Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004; 269: 29-35. (Pubitemid 38032821)
21. Weiss HM, Fresneau M, Moenius T, et al. Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Drug Metab Dispos 2008; 36: 1812-8.
22. Draelos Z, Nayak A, Pariser D, et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602-9. (Pubitemid 41399926)
23. Undre NA, Moloney FJ, Ahmadi S, et al. Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult with moderate to severe atopic dermatitis. Br J Dermatol 2009; 160: 665-9.
24. Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 2005; 211: 174-87. (Pubitemid 41160263)
25. Mandelin JM, Rubins A, Remitz A, et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int J Dermatol 2012; 51: 104-10.
26. Hofman T, Cranswick N, Kuna P, et al. Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. Arch Dis Child 2006; 91: 905-10. (Pubitemid 44690203)
27. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150: 554-62. (Pubitemid 38446313)
28. Remitz A, Harper J, Rustin M, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. Acta Derm Venereol 2007; 87: 54-61. (Pubitemid 46225392)
29. Reitamo S, Rustin M, Harper J, et al. 0.1% Tacrolimus Ointment Long-term Follow-up Study Group. A 4 year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol 2008; 159: 942-51.
30. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002; 110: e2.
31. Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006; 61: 375-81. (Pubitemid 43381816)
32. Ho VC, Gupta A, Kaufmann R, et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142: 155-62. (Pubitemid 36232905)
33. Meurer M, Fartasch M, Albrecht G, et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-72. (Pubitemid 38736667)
34. Paller AS, Lebwohl M, Fleischer AB, et al. Tacrolimus ointment is mor effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 2005; 52: 810-22. (Pubitemid 40614645)